Buy Rating for Lipocine Driven by Innovative Drug Delivery and Promising Pipeline

Yi Chen, an analyst from H.C. Wainwright, has initiated a new Buy rating on Lipocine (LPCN).

Yi Chen has given his Buy rating due to a combination of factors related to Lipocine’s innovative drug delivery platform and promising pipeline. Lipocine’s Lip’ral technology enables the oral delivery of molecules that were previously difficult to administer orally, potentially improving patient compliance and safety. The company’s first commercialized product, TLANDO, has already been approved by the FDA for testosterone replacement therapy, and Lipocine has established multiple commercial partnerships to market it both in the U.S. and internationally.
Yi Chen’s rating is also based on the potential of Lipocine’s lead pipeline candidate, LPCN 1154, an oral formulation for treating postpartum depression. The company has completed key pharmacokinetic studies demonstrating bioequivalence with the intravenous version of brexanolone, which is already FDA-approved. The positive results from these studies, along with the initiation of a Phase 3 trial, suggest that LPCN 1154 could significantly enhance Lipocine’s market value. These developments underpin the Buy rating and the 12-month price target of $8.

Chen covers the Healthcare sector, focusing on stocks such as Vivani Medical, Opko Health, and Clearside Biomedical. According to TipRanks, Chen has an average return of -13.3% and a 31.84% success rate on recommended stocks.